Heterogeneity in DCE-MRI parametric maps: a biomarker for treatment response?
- 18 February 2011
- journal article
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 56 (6), 1601-1616
- https://doi.org/10.1088/0031-9155/56/6/006
Abstract
This study aims to quantify the heterogeneity of tumour enhancement in dynamic contrast-enhanced MRI (DCE-MRI) using texture analysis methods. The suitability of the coherence and the fractal dimension to monitor tumour response was evaluated in 18 patients with limb sarcomas imaged by DCE-MRI pre- and post-treatment. According to the histopathology, tumours were classified into responders and non-responders. Pharmacokinetic (K(trans)) and heuristic model-based parametric maps (slope, max enhancement, AUC) were computed from the DCE-MRI data. A substantial correlation was found between the pharmacokinetic and heuristic model-based parametric maps: ρ = 0.56 for the slope, ρ = 0.44 for maximum enhancement, and ρ = 0.61 for AUC. From all four parametric maps, the enhancing fraction, and the heterogeneity features (i.e. coherence and fractal dimension) were determined. In terms of monitoring tumour response, using both pre- and post-treatment DCE-MRI, the enhancing fraction and the coherence showed significant differences between the response group and the non-response group (i.e. the highest sensitivity (91%) for K(trans), and the highest specificity (83%) for max enhancement). In terms of treatment prediction, using solely the pre-treatment DCE-MRI, the enhancing fraction and coherence discriminated between responders and non-responders. For prediction, the highest sensitivity (91%) was shared by K(trans), slope and max enhancement, and the highest specificity (71%) was achieved by K(trans). On average, tumours that responded showed a high enhancing fraction and high coherence on the pre-treatment scan. These results suggest that specific heterogeneity features, computed from both pharmacokinetic and heuristic model-based parametric maps, show potential as a biomarker for monitoring tumour response.Keywords
This publication has 42 references indexed in Scilit:
- Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast CancerClinical Cancer Research, 2008
- Glioma Grading by Using Histogram Analysis of Blood Volume Heterogeneity from MR-derived Cerebral Blood Volume MapsRadiology, 2008
- Dynamic contrast‐enhanced magnetic resonance imaging of human melanoma xenografts with necrotic regionsJournal of Magnetic Resonance Imaging, 2007
- Dynamic Contrast-Enhanced MRI of Malignant Pleural MesotheliomaSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor‐α and melphalan for limb‐threatening soft tissue sarcomaCancer, 2006
- One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit MetastasesAnnals of Surgery, 2004
- Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance ImagingJournal of Clinical Oncology, 2003
- Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenograftsMagnetic Resonance Imaging, 2003
- Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity SarcomasAnnals of Surgery, 1996
- Chemotherapy of CancerAnnals of Surgery, 1958